Key Takeaways TEM trades near $70.61 against a $75 target, with upside tied to execution and regulatory progress.Valuation implies 8.6x forward sales, hinging on pricing and reimbursement improvement into 2026.Genomics growth, data bookings, and regulatory milestones will drive margin and EBITDA gains.Tempus AI (TEM) has rallied hard in 2025 and now trades close to its 6–12 month target. Progress from regulators and steady execution will be key.The trend is strong, but slow booking-to-revenue conversion and ...

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with po ...